KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer

Breast Cancer Research and Treatment

Volumn 132, Issue 2, 2012, Pages 391-409

  Anbalagan, Muralidharan ^a   Carrier, Latonya ^a   Glodowski, Seth ^a   Hangauer, David ^b   Shan, Bin ^a   Rowan, Brian G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Breast cancer; KX 01; Preclinical; Src kinase inhibitor; Synergy; Tamoxifen

Indexed keywords

CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; CELL PROTEIN; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; KX 01; PROGESTERONE RECEPTOR; PROTEIN CDC25C; PROTEIN MPM2; PROTEIN TYROSINE KINASE INHIBITOR; SERINE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL NUCLEUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME REGULATION; EVENING DOSAGE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MORNING DOSAGE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT;

EID: 85028101671     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1513-3     Document Type: Article

References (50)

1. Sakorafas GH, Farley DR, Peros G (2008) Recent advances and current controversies in the management of DCIS of the breast. Cancer Treat Rev 34(6):483-497. doi:10.1016/j.ctrv.2008.03.001
2. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project p-1 study. J Natl Cancer Inst 90(18):1371-1388 (Pubitemid 28439961)
3. Swerdlow AJ, Jones ME (2005) Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 97(5):375-384. doi:10.1093/jnci/dji057 (Pubitemid 40425956)
4. Decensi A, Gandini S, Serrano D, Cazzaniga M, Pizzamiglio M, Maffini F, Pelosi G, Daldoss C, Omodei U, Johansson H, Macis D, Lazzeroni M, Penotti M, Sironi L, Moroni S, Bianco V, Rondanina G, Gjerde J, Guerrieri-Gonzaga A, Bonanni B (2007) Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. J Clin Oncol 25(27):4201-4209. doi:10.1200/JCO.2006.09.4318 (Pubitemid 47548559)
5. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ (2000) Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-src interactions in breast cancer. Breast Cancer Res 2(3):203-210 (Pubitemid 32223586)
6. Reissig D, Clement J, Sanger J, Berndt A, Kosmehl H, Bohmer FD (2001) Elevated activity and expression of src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue. J Cancer Res Clin Oncol 127(4):226-230
7. Elsberger B, Tan BA, Mitchell TJ, Brown SB, Mallon EA, Tovey SM, Cooke TG, Brunton VG, Edwards J (2009) Is expression oractivation of src kinase associated with cancer-specific survival in er-, pr- and her2-negative breast cancer patients? Am J Pathol 175(4):1389-1397. doi:10.2353/ajpath.2009.090273
8. Fox EM, Bernaciak TM, Wen J, Weaver AM, Shupnik MA, Silva CM (2008) Signal transducer and activator of transcription 5b, c-src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Mol Endocrinol 22(8):1781-1796. doi:10.1210/me.2007-0419
9. Hiscox S, Morgan L, Green T, Nicholson RI (2006) Src as atherapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Relat Cancer 13 Suppl 1:S53-S59. doi:10.1677/erc.1.01297 (Pubitemid 46222445)
10. Desouki MM, Rowan BG (2004) Src kinase and mitogen-activated protein kinases in the progression from normal to malignant endometrium. Clin Cancer Res 10(2):546-555 (Pubitemid 38173993)
11. Shah YM, Rowan BG (2005) The src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity. Mol Endocrinol 19(3):732-748. doi:10.1210/me.2004-0298 (Pubitemid 40349444)
12. Rouanet P, Linares-Cruz G, Dravet F, Poujol S, Gourgou S, Simony-Lafontaine J, Grenier J, Kramar A, Girault J, Le Nestour E, Maudelonde T (2005) Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen. J Clin Oncol 23(13):2980-2987. doi:10.1200/JCO.2005.06.064 (Pubitemid 46224117)
13. Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F, Jove R (2008) Ski-606 (bosutinib), anovel src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 7(5):1185-1194. doi:10.1158/1535-7163.MCT-08-0126
14. Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, Pledger WJ, Jove R (2007) Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on src kinase for survival. Cancer Res 67(6):2800-2808. doi:10.1158/0008-5472.CAN-06- 3469 (Pubitemid 46548969)
15. Kim H, Laing M, Muller W (2005) c-Src-null mice exhibit defects in normal mammary gland development and ERalpha signaling. Oncogene 24(36):5629-5636. doi:10.1038/sj.onc.1208718 (Pubitemid 43119356)
16. Feng W, Webb P, Nguyen P, Liu X, Li J, Karin M, Kushner PJ (2001) Potentiation of estrogen receptor activation function 1 (af-1) by Src/JNK through a serine 118-independent pathway. Mol Endocrinol 15(1):32-45 (Pubitemid 32156039)
17. Jr DH (2007) Kxo1: compositions for treating cell proliferation disorders. 7300931 B2, 27
18. Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, Lambert-van der Brempt C, Morgentin R, Norman RA, Olivier A, Otterbein L, Ple PA, Warin N, Costello G (2006) N-(5-chloro-1, 3-benzodioxol-4-yl)-7-[2-(4- methylpiperazin-1-yl) ethoxy]-5- (tetrahydro-2 h-pyran-4-yloxy)quinazolin-4- amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem 49(22):6465-6488. doi:10.1021/jm060434q
19. Li Z, Carrier L, Belame A, Thiyagarajah A, Salvo VA, Burow ME, Rowan BG (2009) Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis. Breast Cancer Res Treat 118(1):33-43. doi:10.1007/s10549-008-0216- x
20. Chou TC (1991) Synergism and antagonism in chemotherapy. The median-effect principle and the combination index for quantitation of synergism and antagonism. Academic Press, San Diego
21. Chen Y, Guggisberg N, Jorda M, Gonzalez-Angulo A, Hennessy B, Mills GB, Tan CK, Slingerland JM (2009) Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clin Cancer Res 15(10):3396-3405. doi:10.1158/1078- 0432.CCR-08-3127
22. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ (2007) Dasatinib, anorally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple- negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105(3):319-326. doi:10.1007/s10549-006-9463-x (Pubitemid 47596452)
23. Doree M, Hunt T (2002) From Cdc2 toCdk1: when did the cell cycle kinase join its cyclin partner? J Cell Sci 115(Pt 12):2461-2464 (Pubitemid 34778063)
24. Berry LD, Gould KL (1996) Regulation of Cdc2 activity by phosphorylation at T14/Y15. Prog Cell Cycle Res 2:99-105
25. Ramalingam S, Natarajan G, Schafer C, Subramaniam D, May R, Ramachandran I, Queimado L, Houchen CW, Anant S (2008) Novel intestinal splice variants of rna-binding protein CUGBP2: isoform-specific effects on mitotic catastrophe. Am J Physiol Gastrointest Liver Physiol 294(4):G971-G981. doi:10.1152/ajpgi.00540. 2007 (Pubitemid 351520057)
26. Bonnet J, Mayonove P, Morris MC (2008) Differential phosphorylation of Cdc25c phosphatase in mitosis. Biochem Biophys Res Commun 370(3):483-488. doi:10.1016/j.bbrc.2008.03.117
27. Kuang J, Ashorn CL, Gonzalez-Kuyvenhoven M, Penkala JE (1994) Cdc25 isone of the MPM-2 antigens involved in the activation of maturation-promoting factor. Mol Biol Cell 5(2):135-145 (Pubitemid 24108460)
28. Castedo M, Perfettini JL, Roumier T, Kroemer G (2002) Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ 9(12):1287-1293. doi:10.1038/sj.cdd.4401130 (Pubitemid 36097698)
29. Pascreau G, Arlot-Bonnemains Y, Prigent C (2003) Phosphorylation of histone and histone-like proteins by aurora kinases during mitosis. Prog Cell Cycle Res 5:369-374
30. Roninson IB, Broude EV, Chang BD (2001) If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 4(5):303-313. doi:10.1054/drup.2001.0213 (Pubitemid 34456384)
31. Adjei AA CR, Kurzrock R, Gordon GS, Hangauer D, et al. (2009) Results of a phase i trial of KX2-391, a novel non-atp competitive substrate-pocket directed src inhibitor, in patients with advanced malignancies. J Clin Oncol 27 (suppl; abstr 3511):1
32. Hiscox S, Jordan NJ, Smith C, James M, Morgan L, Taylor KM, Green TP, Nicholson RI (2009) Dual targeting of src and er prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res Treat 115(1):57-67. doi:10.1007/s10549-008-0058-6
33. Morgan L, Gee J, Pumford S, Farrow L, Finlay P, Robertson J, Ellis I, Kawakatsu H, Nicholson R, Hiscox S (2009) Elevated src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol Ther 8(16):1550-1558
34. Chu I, Sun J, Arnaout A, Kahn H, Hanna W, Narod S, Sun P, Tan CK, Hengst L, Slingerland J (2007) P27 phosphorylation bysrc regulates inhibition of cyclin e-cdk2. Cell 128(2):281-294. doi:10.1016/j.cell.2006.11.049 (Pubitemid 46123510)
35. Herynk MH, Beyer AR, Cui Y, Weiss H, Anderson E, Green TP, Fuqua SA (2006) Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther 5(12):3023-3031. doi:10.1158/1535-7163.MCT-06-0394 (Pubitemid 46092043)
36. Filardo EJ, Quinn JA, Frackelton AR Jr, Bland KI (2002) Estrogen action via the g protein-coupled receptor, GPR30: Stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 16(1):70-84 (Pubitemid 34044499)
37. Song RX, Zhang Z, Santen RJ (2005) Estrogen rapid action via protein complex formation involving ERalpha and Src. Trends Endocrinol Metab 16(8):347-353. doi:10.1016/j.tem.2005.06.010 (Pubitemid 41338739)
38. Weigel NL, Moore NL (2007) Steroid receptor phosphorylation: akey modulator of multiple receptor functions. Mol Endocrinol 21(10):2311-2319. doi:10.1210/me.2007-0101 (Pubitemid 47529347)
39. Castano E, Vorojeikina DP, Notides AC (1997) Phosphorylation of serine-167 on the human oestrogen receptor is important for oestrogen response element binding and transcriptional activation. Biochem J 326(Pt 1):149-157 (Pubitemid 27386929)
40. Arnold SF, Obourn JD, Jaffe H, Notides AC (1995) Phosphorylation of the human estrogen receptor by mitogen-activated protein kinase and casein kinase ii: consequence on DNA binding. J Steroid Biochem Mol Biol 55(2):163-172
41. Roche S, Fumagalli S, Courtneidge SA (1995) Requirement for Src family protein tyrosine kinases in G2 for fibroblast cell division. Science 269(5230):1567-1569
42. Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N (1999) Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res 59(24):6145-6152 (Pubitemid 30035635)
43. Gonzalez L, Agullo-Ortuno MT, Garcia-Martinez JM, Calcabrini A, Gamallo C, Palacios J, Aranda A, Martin-Perez J (2006) Role of c-Src in human MCF7 breast cancer cell tumorigenesis. J Biol Chem 281(30):20851-20864. doi:10.1074/jbc.M601570200 (Pubitemid 44115426)
44. Kasahara K, Nakayama Y, Nakazato Y, Ikeda K, Kuga T, Yamaguchi N (2007) Src signaling regulates completion of abscission in cytokinesis through ERK/MAPK activation at the midbody. J Biol Chem 282(8):5327-5339. doi:10.1074/jbc. M608396200 (Pubitemid 47093765)
45. Garcia-Martinez JM, Calcabrini A, Gonzalez L, Martin-Forero E, Agullo-Ortuno MT, Simon V, Watkin H, Anderson SM, Roche S, Martin-Perez J (2010) A non-catalytic function of the Src family tyrosine kinases controls prolactin-induced Jak2 signaling. Cell Signal 22(3):415-426. doi:10.1016/j.cellsig.2009.10.013
46. Finlay D, Vuori K (2007) Novel noncatalytic role for caspase-8 in promoting Src-mediated adhesion and erk signaling in neuroblastoma cells. Cancer Res 67(24):11704-11711. doi:10.1158/0008-5472.CAN-07-1906
47. Lagadec C, Adriaenssens E, Toillon RA, Chopin V, Romon R, Van Coppenolle F, Hondermarck H, Le Bourhis X (2008) Tamoxifen and trail synergistically induce apoptosis in breast cancer cells. Oncogene 27(10):1472-1477. doi:10.1038/sj.onc.1210749 (Pubitemid 351317455)
48. Decensi A, Gandini S, Guerrieri-Gonzaga A, Johansson H, Manetti L, Bonanni B, Sandri MT, Barreca A, Costa A, Robertson C, Lien EA (1999) Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 17(9):2633-2638 (Pubitemid 29415218)
49. Park SI, Shah AN, Zhang J, Gallick GE (2007) Regulation of angiogenesis and vascular permeability by src family kinases: opportunities for therapeutic treatment of solid tumors. Expert Opin Ther Targets 11(9):1207-1217. doi:10.1517/14728222.11.9.1207 (Pubitemid 47527325)
50. Garvin S, Nilsson UW, Dabrosin C (2005) Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Br J Cancer 93(9):1005-1010. doi:10.1038/sj.bjc.6602824 (Pubitemid 41548394)